Uneven impacts of COVID-19 on residents' utilization of urban parks: A case study of Guangzhou, China.

As COVID-19 increased people's dependency on urban parks for physical and psychological well-being, it also has uncertain impacts on park utilization. Understanding these impacts and how the pandemic has contributed to them is an issue that warrants urgent attention. We used multi-source spatio-temporal data to examine urban park use before and during COVID-19 in Guangzhou, China, and constructed a set of regression models to evaluate the associated factors.

Proteomic analysis of grape berry skin responding to sunlight exclusion.

The most obvious effect of sunlight exclusion from grape clusters is the inhibition of anthocyanin biosynthesis in the berry skin so that no color develops. Two-dimensional gel electrophoresis coupled with mass spectrometry was used to characterize the proteins isolated from berry skins that developed under sunlight exclusion versus those from sunlight-exposed berries. Among more than 1500 spots resolved in stained gels, the accumulation patterns of 96 spots differed significantly between sunlight-excluded berry skin and that of sunlight-exposed control berries.

Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.

Chronic myelogenous leukemia (CML) results from transformation of a primitive hematopoietic cell by the BCR/ABL gene. The specific BCR/ABL signaling mechanisms responsible for transformation of primitive human hematopoietic cells are not well defined. Previous studies have suggested that constitutively activated tyrosine kinase activity plays an important role for in abnormal proliferation of CML progenitors but has not clearly defined its role in abnormal adhesion and migration.

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) has shown remarkable efficacy in the treatment of chronic myelogenous leukemia (CML), with a high proportion of patients achieving complete cytogenetic responses (CCRs). However, it is not clear whether remissions will be durable and whether imatinib mesylate can eliminate the malignant primitive progenitors in which the disease arises. We investigated whether residual BCR/ABL+ hematopoietic progenitors were present in patients who achieved CCRs with imatinib mesylate treatment.